21:31 , Apr 1, 2019 |  BC Extra  |  Company News

Salix licenses new NASH target from UCLA

Salix is entering the NASH and NAFLD race with a license from UCLA to a compound against a new target in the space. Salix Pharmaceuticals Ltd. gained a license to develop and commercialize a fusion...
00:08 , Jan 23, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Migraine In vitro and rat studies identified a mAb against the ADCYAP1-derived peptides PACAP-38 and PACAP-27 that could help treat migraine. In vitro screening of B cell cultures of PACAP-38-immunized rabbits for mAbs that...
17:37 , Jan 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Spinal muscular atrophy (SMA) Cell culture and mouse studies suggest a modified ADCYAP1 -derived peptide could help treat spinal and bulbar muscular atrophy (SBMA). In a mouse neuronal cell line expressing an SBMA-associated androgen...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Cu-64-TP3805 diagnostic data

Researchers at Thomas Jefferson University reported data from 13 breast cancer patients showing that Positron Emission Mammography (PEM) imaging using Cu-64-TP3805 had 100% sensitivity and 100% specificity for distinguishing malignant from benign breast cancer lesions....
07:00 , Mar 17, 2011 |  BC Innovations  |  Targets & Mechanisms

The hormone trigger in PTSD

Post-traumatic stress disorder is thought to involve changes in the circuitry of brain regions related to fear, although the specific molecular players have been elusive. Now, U.S. researchers have evidence that dysregulation of a brain...
08:00 , Mar 10, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Post-traumatic stress disorder (PTSD) Adenylate cyclase activating polypeptide pituitary (ADCYAP1; PACAP); adenylate cyclase activating polypeptide 1 pituitary receptor type I (ADCYAP1R1; PAC1) Studies in...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Clinical News

NuView preclinical data

In a mouse model of breast cancer, positron emission tomography (PET) imaging using NVB-64 identified all 8 malignant tumors and no benign tumors. The control imaging agent F-18-fluorodeoxyglucose (F-18-FDG) identified 4 malignant tumors, missed 4...
07:00 , May 21, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Adenylate cyclase activating polypeptide pituitary (ADCYAP1; PACAP); ADCYAP1 receptor type 1 (ADCYAP1R1; PAC1) SAR analysis and in vitro studies suggest...
07:00 , Jun 26, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Pituitary adenylate cyclase-activating peptide (PACAP); proopiomelanocortin (POMC); b-endorphin (BEP) Studies in cell culture and rats suggest that neuronal...
07:00 , Apr 4, 2005 |  BioCentury  |  Tools & Techniques

Misleading tumor cells

DNA-damaging agents such as cisplatins are widely used in cancer treatment but have a narrow therapeutic window: too low a dose allows for DNA repair, and too high a dose is widely cytotoxic. Researchers at...